Trials / Completed
CompletedNCT06324006
A Phase 1 Trial of LIB-01 in Healthy Participants.
A Phase 1, Randomized, Double-blind, Parallel and Placebo-controlled Single and Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of LIB-01 in Healthy Participants.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Dicot AB · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetics of LIB-01 in healthy male participants. The main questions it aims to answer are: * How safe and tolerable is LIB-01 when given once or repeatedly at different dose levels. * What are the pharmacokinetic characteristics of LIB-01 Participants will receive LIB-01 and be followed up for safety and pharmacokinetics by: * Adverse events * ECG * Blood sampling for laboratory parameters and pharmacokinetic analysis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LIB-01 | LIB-01 oral suspension |
| OTHER | Placebo | Placebo oral suspension |
Timeline
- Start date
- 2023-08-25
- Primary completion
- 2024-04-23
- Completion
- 2024-05-29
- First posted
- 2024-03-21
- Last updated
- 2024-05-30
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT06324006. Inclusion in this directory is not an endorsement.